Seeking Alpha

Genzyme Corp. (GENZ)

()

News & PR
Market Currents

Buzz
Twitter: GENZ

Business Intelligence
Transcripts
Events
Key Developments

Analysis - Latest Articles by most recent | most commented

Will 2009's Losers Become 2010's Winners?

Dec 14 • Alan Brochstein • 6 Comments
Best and Worst Since the March 9th Low

Dec 11 • Bespoke Investment Group • 5 Comments
Genzyme: Positive Development on the Lumizyme Front

Dec 3 • Mark Mitchell • 3 Comments
Dyax: FDA Approval Boosts Prospects

Dec 3 • EP Vantage • Comment!
'Black Friday' Data Weighs on Futures

Nov 30 • optionMONSTER • Comment!
Genzyme's Renagel / Renvela Franchise: Investors Would Be Wise to Reevaluate

Nov 25 • Mark Mitchell • 2 Comments
Genzyme's Very Bad Year

Nov 23 • EP Vantage • 5 Comments
Genzyme's Problems Continue with Discontinuation of Kidney Drug Development

Nov 19 • Zacks.com • Comment!
Lumizyme Rejected Again: Downgrading Genzyme Recommendation from Buy to Hold

Nov 17 • Mark Mitchell • Comment!
Genzyme: Key Pipeline Setback Continues Negative Sentiment

Nov 17 • Mark Mitchell • Comment!
Genzyme: Haunted by Contamination

Nov 16 • Zacks.com • Comment!
Another Manufacturing Setback for Genzyme

Nov 16 • Mark Mitchell • 8 Comments
Friday Options Recap

Nov 13 • Frederic Ruffy • Comment!
Wall Street Breakfast: Must-Know News

Nov 2 • SA Editor Eli Hoffmann • 18 Comments
Healthcare Profits: Assessing Company Sensitivity to Obamacare

Oct 30 • Richard Shaw • 11 Comments
Genzyme: Focusing on Lumizyme Approval

Oct 30 • Mark Mitchell • Comment!
Venture Capital Flows to Biotech as Public Financing Takes a Breather

Oct 25 • The Burrill Report • Comment!
Biotech: Q3 Market Update

Oct 16 • R. Scott Raynovich • 1 Comment
Genzyme Fails to Receive Approval for Leukemia Drug

Oct 9 • Zacks.com • Comment!
Trial Setback Is Welcome News for Genzyme, But Don't Get Too Excited

Oct 6 • Mark Mitchell • 3 Comments
BioMed News Bytes: Dendreon, Chelsea, Cytori, Cephalon, OraSure, Genzyme, Lixte

Sep 25 • Mike Havrilla • 3 Comments
Sell Genzyme Near Term Due to Continued Manufacturing Challenges

Sep 24 • Mark Mitchell • 2 Comments
Biotech News Bytes: Genzyme, ImmunoCellular, Momenta, Novo Nordisk

Sep 23 • Mike Havrilla • Comment!
China Biotech Week in Review: SFDA Approvals All Around

Sep 20 • ChinaBio Today • Comment!
Genzyme Pushes to Expand Product Line in China

Sep 20 • ChinaBio Today • Comment!
Genzyme's MS Drug Shows Promise

Sep 18 • Zacks.com • Comment!
Genzyme: Short Term Traders Are Throwing Out the Baby with the Bathwater

Sep 16 • Ken Majmudar • Comment!
Biotech Busy with Bevy of Small Deals

Sep 12 • The Burrill Report • 1 Comment
Will the FDA Approve Allos Therapeutics' New Cancer Drug?

Sep 4 • Prohost Biotech • Comment!
Clolar Decision Aside, Genzyme's Still a Near-Term Sell

Sep 2 • Mark Mitchell • Comment!
Why Would an Insider Be Selling Protalix Shares Now of All Times?

Sep 2 • Shlomi Cohen • 2 Comments
Options Trader: August Retrospective

Aug 29 • Philip Davis • Comment!
Genzyme Appears Overbought: Reiterating Near-Term Sell

Aug 27 • Mark Mitchell • Comment!
Vion Pharmaceuticals' Onrigin: Good Chance of FDA Approval

Aug 26 • R. Saito • 25 Comments
Protalix Biotherapeutics: FDA Fast Track for Gaucher Treatment

Aug 26 • BioPharma Investor • 4 Comments
8 'Bathwater Babies' and 20 'Dogs with Fleas' for the Week

Aug 26 • J Clinton Hill • 4 Comments
Stocks that Could Benefit from Health Reform

Aug 23 • Zacks.com • 7 Comments
Another Blow for Genzyme

Aug 18 • Zacks.com • Comment!
Genzyme: More Negative News

Aug 18 • Mark Mitchell • 3 Comments
Avigen Still a Good Value

Aug 18 • Greenbackd • 1 Comment
3 Biotechs, 3 Big Pharma Plays for the Coming Generics Boom

Aug 18 • The Curious Investor • 4 Comments

Genzyme Corp. (GENZ)

Analysis - Latest Articles by most recent | most commented

The Seeking Alpha 100

Fastest Climbers

Top Commenters

Top Instabloggers

Top StockTalkers